Pharma major Lupin Ltd has received the final approval from the United States Food and Drugs Administration (USFDA) to market a generic version of an oral conceptive called Lutera Tablets.
The sales of the tablet were approximately $103.6 million in the US market and Lupin will begin marketing the generic version shortly, the company said.
Lupin is the fifth largest generics player in the US with a share of 5.1%. It is a significant player in the cardiovascular, diabetology, asthma and pediatric segments, holding global leadership in the anti-tuberculosis area.
